Core Insights - Tempus AI's second-quarter results exceeded Wall Street expectations, leading to increased investor confidence [2][5] - The company raised its full-year sales guidance following strong performance in Q2 [2][6] Financial Performance - Tempus AI reported an adjusted loss of $0.22 per share on revenue of $314.6 million for Q2, outperforming analyst estimates of a $0.25 loss on $297.8 million in sales [4] - Sales increased approximately 90% year over year, driven by strong growth in the genomics segment [5] Future Outlook - The company now expects full-year revenue to reach approximately $1.26 billion, indicating an annual sales growth of around 86% [6] - Tempus AI anticipates adjusted EBITDA of $5 million for the year, reflecting a $110 million improvement over the previous year's performance [7]

Core Insights - Cohere has experienced significant growth, with annualized revenue reaching $70 million, more than tripling since March of the previous year [1] - The company is considering allowing the sale of employee shares, which may provide investors insight into its valuation in the competitive enterprise AI software market [2] - Following the potential share sale, a major Series E funding round is anticipated by some investors [2]